Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

LAUR Repository

Show simple item record

dc.contributor.author Kesmodel, Susan
dc.contributor.author Ellis, Lee
dc.contributor.author Lin, E.
dc.contributor.author Chang, George
dc.contributor.author Abdalla, Eddie
dc.contributor.author Kopetz, Scott
dc.contributor.author Vauthey, Jean-Nicolas
dc.contributor.author Rodriguez-Bigas, Miguel
dc.contributor.author Curley, Steven
dc.contributor.author Feig, Barry
dc.date.accessioned 2015-11-17T07:50:09Z
dc.date.available 2015-11-17T07:50:09Z
dc.date.copyright 2008
dc.date.issued 2015-11-17
dc.identifier.issn 0732-183X en_US
dc.identifier.uri http://hdl.handle.net/10725/2590
dc.description.abstract Purpose Although bevacizumab (BV) increases survival rates when used with chemotherapy (CTX) in patients who have metastatic colorectal cancer (CRC), an increase in wound complications has been observed in patients who undergo surgery while receiving BV. We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases. Patients and Methods Two subgroups of patients who received neoadjuvant CTX + BV (n = 81) or CTX alone (n = 44) were identified from a database of patients who underwent surgery for CRC liver metastases. Univariate and multivariate logistic regression models were used to evaluate the association of patient and tumor characteristics, neoadjuvant therapy, and operative factors with postoperative complications. Results Postoperative complications developed in 40 patients (49%) who received CTX + BV and 19 patients (43%) who received CTX. The median time from BV discontinuation to surgery was 58 days (range, 31 to 117 days). No significant associations were identified between BV use and timing of BV discontinuation and postoperative complications. On multivariate analysis, lower serum albumin and concomitant surgical procedures were associated with an increased risk of developing any complication (P = .035 and .023, respectively), and lower serum albumin was associated with hepatobiliary complications (P = .016). Conclusion Neither the use of BV nor timing of BV administration was associated with an increase in complication rates. These data suggest that the combination of BV with neoadjuvant CTX in patients who have CRC liver metastases does not increase surgical complications. To determine the optimal timing of surgery in patients receiving neoadjuvant BV, confirmatory prospective studies are required. en_US
dc.language.iso en en_US
dc.title Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Clinical Oncology en_US
dc.journal.volume 26 en_US
dc.journal.issue 32 en_US
dc.article.pages 5254-5260 en_US
dc.identifier.doi http://dx.doi.org/10.1200/JCO.2008.17.7857 en_US
dc.identifier.ctation Kesmodel, S. B., Ellis, L. M., Lin, E., Chang, G. J., Abdalla, E. K., Kopetz, S., ... & Feig, B. W. (2008). Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. Journal of Clinical Oncology, 26(32), 5254-5260. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://jco.ascopubs.org/content/26/32/5254.short

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account